Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling

Background Predicting drug pharmacokinetics in pregnant women including placental drug transfer remains challenging. This study aimed to develop and evaluate maternal–fetal physiologically based pharmacokinetic models for two antiretroviral drugs, dolutegravir and raltegravir.

Saved in:
Bibliographic Details
Published inClinical pharmacokinetics Vol. 59; no. 11; pp. 1433 - 1450
Main Authors Liu, Xiaomei I., Momper, Jeremiah D., Rakhmanina, Natella Y., Green, Dionna J., Burckart, Gilbert J., Cressey, Tim R., Mirochnick, Mark, Best, Brookie M., van den Anker, John N., Dallmann, André
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.11.2020
Springer Nature B.V
Subjects
Acquired immune deficiency syndrome
AIDS
Antiretroviral drugs
Clinical trials
Disease transmission
Drug dosages
Enzymes
Fetuses
Gestational age
HIV
Human immunodeficiency virus
Infections
Internal Medicine
Medicine
Medicine & Public Health
Original Research Article
Pediatrics
Pharmacokinetics
Pharmacology
Pharmacology/Toxicology
Pharmacotherapy
Plasma
Pregnancy
Veins & arteries
United States > US
Online AccessGet full text

Cover

More Information
Summary:Background Predicting drug pharmacokinetics in pregnant women including placental drug transfer remains challenging. This study aimed to develop and evaluate maternal–fetal physiologically based pharmacokinetic models for two antiretroviral drugs, dolutegravir and raltegravir.
ISSN:0312-5963
1179-1926
DOI:10.1007/s40262-020-00897-9